Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001072613-24-000252
Filing Date
2024-02-14
Accepted
2024-02-14 15:18:45
Documents
1
Group Members
ARCH VENTURE FUND IX OVERAGE, L.P.ARCH VENTURE PARTNERS IX OVERAGE, L.P.ARCH VENTURE PARTNERS IX, L.P.ARCH VENTURE PARTNERS IX, LLCCLINTON BYBEEKEITH CRANDELLROBERT NELSEN

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND IX, L.P. - LYELL IMMUNOPHARMA -- SCH 13G/A(#1) arch-sch13g_18793.htm SC 13G/A 275304
  Complete submission text file 0001072613-24-000252.txt   277144
Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund IX, L.P. (Filed by) CIK: 0001666306 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Subject) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-93402 | Film No.: 24636717
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)